Roche receives FDA approval for Tecentriq and Roche Holding stock costs EUR 381.90

Published on 10/09/2026 at 12:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Core earnings per share grew 11.00 percent in fiscal 2025. Roche Holding stock costs EUR 381.90 on October 9, 2026 after EUR 380.88.

Key points in brief

Roche received U.S. FDA approval for a Tecentriq combination in stage III dMMR colon cancer on October 9, 2026.
The ATOMIC study cut recurrence or death risk by 50.00 percent, with 36-month disease-free survival of 86.00 percent versus 76.00 percent.
Roche Holding stock was trading at EUR 381.90 at Lang & Schwarz on October 9, 2026, up 0.27 percent versus EUR 380.88.
Roche's next third-quarter sales update is scheduled for October 22, 2026, before the Swiss exchange opens.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche received U.S. FDA approval for a Tecentriq combination on October 9, 2026, while Roche Holding stock was trading at EUR 381.90 at Lang & Schwarz. According to Roche, the approval covers Tecentriq and Tecentriq Hybreza with chemotherapy for stage III dMMR colon cancer and marks Tecentriq's twelfth U.S. indication.

Three milestones shape the pipeline

On September 10, 2026, GlobeNewswire reported that Roche's Enspryng application received FDA Priority Review, supported by data showing a 68.00 percent reduction in relapse risk.

On September 28, 2026, Roche outlined a 2030 goal of producing 20 new medicines, according to finanzen.at. That plan gives the FDA decision a wider pipeline context, although research output remains a multi-year execution issue.

What does the approval mean for oncology?

The ATOMIC study supplies the key commercial and clinical proof point. Roche said the combination reduced the risk of disease recurrence or death by 50.00 percent compared with chemotherapy alone, while 36-month disease-free survival reached 86.00 percent versus 76.00 percent for chemotherapy alone.

The approval expands Tecentriq into an adjuvant setting after surgery for patients with stage III dMMR colon cancer. Roche also said it is pursuing additional regulatory filings, extending the potential geographic reach beyond the United States.

Dates point to the next sales test

Roche's investor calendar sets the third-quarter 2026 sales release for October 22, 2026, before the Swiss Stock Exchange opens, followed by a presentation at 2:00 p.m. CEST, according to Roche. The investor-relations calendar also lists the Berenberg Pharma CFO Series for November 2, 2026.

Roche's investor page reports that core earnings per share grew 11.00 percent in fiscal 2025 to CHF 19.46, giving the pipeline news a profitability reference point. It also reports that 39 million patients received Roche medicines in fiscal 2025.

Roche Holding stock stays near its latest level

At Lang & Schwarz, Roche Holding stock was trading at EUR 381.90 on October 9, 2026 at 12:44 p.m. CEST, up 0.27 percent versus the prior close of EUR 380.88. The stock's primary listing is SIX in Swiss francs, where the October 8, 2026 close was CHF 352.70 and market capitalization was CHF 275.44 billion.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.